Weight Loss and Improvements in Quality of Life Associated With Baseline Body-Mass Index in Obese and Overweight Patients Treated With Phentermine/Topiramate Extended-Release
Authors: Timothy Church, MD
a; Ronette L. Kolotkin, PhD
b; Santosh T. Varghese, MD
Affiliations: a Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA;
bDuke University Medical Center and Obesity and Quality of Life Consulting, Durham, NC;
cVIVUS, Inc., Mountain View, CA, USA
AANP 2013: American Association of Nurse Practitioners 28
June 19-23, 2013
The Venetian, The Palazzo, and Sands Expo and Convention Center, Las Vegas, Nevada
Poster Presentation Date:
- Poster Presentation: Thursday, June 20, 4:00 PM to 6:00 PM; Friday, June 21, 4:00 PM to 6:00 PM; Saturday, June 22, 12:30 PM to 2:15 PM
- Exhibit Hall Hours: Thursday, June 20, 10:45 AM to 1:00 PM; Friday, June 21, 11:00 AM to 6:00 PM; Saturday, June 22, 11:00 AM to 2:30 PM
Session Location: The Venetian, The Palazzo and Sands Expo and Convention Center, Exhibit Hall
Prevention of Type 2 Diabetes Mellitus in Subjects With Prediabetes Using Phentermine and Topiramate Extended-Release for 1 Year
Miriam M. Rueger, RN, MPH, RD, CDE
; W. Timothy Garvey, MD
; Lan T. Nguyen
; Craig A. Peterson, MS
University of Alabama at Birmingham, Birmingham, AL;
VIVUS, Inc., Mountain View, CA
(phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts